INFLARX NV's ticker is IFRX and the CUSIP is N44821101. A total of 32 filers reported holding INFLARX NV in Q3 2022. The put-call ratio across all filers is 0.35 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $131 | +12.9% | 75,100 | 0.0% | 0.01% | 0.0% |
| Q1 2024 | $116 | -4.9% | 75,100 | 0.0% | 0.01% | -10.0% |
| Q4 2023 | $122 | -18.1% | 75,100 | +49.9% | 0.01% | -23.1% |
| Q3 2023 | $149 | -33.2% | 50,100 | 0.0% | 0.01% | -31.6% |
| Q2 2023 | $223 | +52.7% | 50,100 | -33.3% | 0.02% | +46.2% |
| Q1 2023 | $146 | -37.3% | 75,100 | 0.0% | 0.01% | -40.9% |
| Q4 2022 | $233 | -99.9% | 75,100 | 0.0% | 0.02% | +10.0% |
| Q3 2022 | $198,000 | +81.7% | 75,100 | 0.0% | 0.02% | +100.0% |
| Q2 2022 | $109,000 | -20.4% | 75,100 | 0.0% | 0.01% | -9.1% |
| Q1 2022 | $137,000 | -61.6% | 75,100 | 0.0% | 0.01% | -59.3% |
| Q4 2021 | $357,000 | +83.1% | 75,100 | 0.0% | 0.03% | +58.8% |
| Q3 2021 | $195,000 | -12.6% | 75,100 | 0.0% | 0.02% | -10.5% |
| Q2 2021 | $223,000 | -23.9% | 75,100 | 0.0% | 0.02% | -29.6% |
| Q1 2021 | $293,000 | +132.5% | 75,100 | +199.2% | 0.03% | +125.0% |
| Q4 2020 | $126,000 | – | 25,100 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,764,888 | $60,571,000 | 13.75% |
| RA Capital Management | 1,967,848 | $67,537,000 | 3.61% |
| Cormorant Asset Management, LP | 1,341,540 | $46,042,000 | 2.99% |
| Redmile Group, LLC | 2,024,900 | $69,495,000 | 2.14% |
| EMORY UNIVERSITY | 90,437 | $3,104,000 | 2.03% |
| Artal Group S.A. | 500,000 | $17,160,000 | 0.45% |
| Birchview Capital, LP | 16,000 | $549,000 | 0.35% |
| Eventide Asset Management | 275,000 | $9,438,000 | 0.35% |
| Rock Springs Capital Management LP | 177,500 | $6,092,000 | 0.22% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,551,959 | $87,583,000 | 0.20% |